RecruitingPhase 2NCT03266640

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients

Sponsor

New York Medical College

Enrollment

20 participants

Start Date

Nov 1, 2018

Study Type

INTERVENTIONAL

Conditions

Cytomegalovirus Infections Primary Immune Deficiency Disorder

Summary

CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

Eligibility

Min Age: 1 MonthMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called viral specific cytotoxic t-lymphocytes for people with cytomegalovirus infections and primary immune deficiency disorder. The study is currently recruiting participants at 9 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGviral specific cytotoxic t-lymphocytes

CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.